Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response

Journal of Immune Based Therapies and Vaccines

Volumn 9, Issue , 2011, Pages

  HogenEsch, Harm ^a   Dunham, Anisa ^a   Hansen, Bethany ^a   Anderson, Kathleen ^a   Maisonneuve, Jean Francois ^b   Hem, Stanley L ^c  

^a PURDUE UNIVERSITY   (United States)

^b PATH   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BACTERIAL ANTIGEN; CELL ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; PNEUMOCOCCUS VACCINE; PROPIOLACTONE; UNCLASSIFIED DRUG; WHOLE CELL BACTERIAL ANTIGEN;

ADSORPTION KINETICS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BLOOD ANALYSIS; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; STORAGE TEMPERATURE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TH17 CELL; WHOLE CELL;

EID: 79960888602     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-9-5     Document Type: Article

References (32)

1. World Health Organization Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Weekly Epidemiological Record 2007, 82:93-104. World Health Organization.
2. Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30:189-209. 10.1055/s-0029-1202938, 19296419.
3. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. 10.1016/S0140-6736(09)61204-6, 19748398.
4. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297:1784-1792. 10.1001/jama.297.16.1784, 17456820.
5. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, George R, Miller E. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011, 8:e1001017. 10.1371/journal.pmed.1001017, 3071372, 21483718.
6. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med 2010, 88:135-142. 10.1007/s00109-009-0579-4, 20049411.
7. Malley R, Lipsitch M, Stack A, Saladino R, Fleisher G, Pelton S, Thompson C, Briles D, Anderson P. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001, 69:4870-4873. 10.1128/IAI.69.8.4870-4873.2001, 98576, 11447162.
8. Malley R, Morse SC, Leite LC, Areas AP, Ho PL, Kubrusly FS, Almeida IC, Anderson P. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 2004, 72:4290-4292. 10.1128/IAI.72.7.4290-4292.2004, 427453, 15213177.
9. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 2005, 102:4848-4853. 10.1073/pnas.0501254102, 555733, 15781870.
10. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4:e1000159. 10.1371/journal.ppat.1000159, 2528945, 18802458.
11. Hem SL, HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6:685-698. 10.1586/14760584.6.5.685, 17931150.
12. Berthold I, Pombo ML, Wagner L, Arciniega JL. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005, 23:1993-1999. 10.1016/j.vaccine.2004.10.014, 15734073.
13. Romero MI, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007, 25:825-833. 10.1016/j.vaccine.2006.09.039, 17014935.
14. Noe SM, Green MA, HogenEsch H, Hem SL. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010, 28:3588-3594. 10.1016/j.vaccine.2010.02.085, 20211692.
15. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005, 280:13406-13414. 10.1074/jbc.M500687200, 15684430.
16. Peek LJ, Martin TT, Elk NC, Pegram SA, Middaugh CR. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 2007, 96:547-557. 10.1002/jps.20762, 17080408.
17. Jiang D, Morefield GL, HogenEsch H, Hem SL. Relationship of adsorption mechanism of antigens by aluminum-containing adjuvants to in vitro elution in interstitial fluid. Vaccine 2006, 24:1665-1669. 10.1016/j.vaccine.2005.09.048, 16246468.
18. Hansen B, Sokolovska A, HogenEsch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007, 25:6618-6624. 10.1016/j.vaccine.2007.06.049, 17681647.
19. Lu YJ, Leite L, Goncalves VM, Dias WD, Liberman C, Fratelli F, Alderson M, Tate A, Maisonneuve JF, Robertson G, et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28:7468-7475. 10.1016/j.vaccine.2010.09.031, 20858450.
20. Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, HogenEsch H, Mancinelli R, Hem SL. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009, 27:888-892. 10.1016/j.vaccine.2008.11.078, 19071182.
21. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005, 23:1588-1595. 10.1016/j.vaccine.2004.07.050, 15694511.
22. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119:1899-1909. 2701860, 19509469.
23. Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun 2010, 78:32-38. 10.1128/IAI.00929-09, 2798221, 19901061.
24. Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 2010, 32:79-90. 10.1007/s00281-009-0191-2, 2855296, 20112107.
25. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999, 274:33419-33425. 10.1074/jbc.274.47.33419, 10559223.
26. Michelsen KS, Aicher A, Mohaupt M, Hartung T, Dimmeler S, Kirschning CJ, Schumann RR. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem 2001, 276:25680-25686. 10.1074/jbc.M011615200, 11316801.
27. Denoel P, Poolman J, Carletti G, Veitch K. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine 2002, 20:2551-2555. 10.1016/S0264-410X(02)00158-5, 12057612.
28. Andreasen C, Powell DA, Carbonetti NH. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 2009, 4:e7079. 10.1371/journal.pone.0007079, 2738961, 19759900.
29. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006, 177:7980-7989.
30. Banus S, Stenger RM, Gremmer ER, Dormans JA, Mooi FR, Kimman TG, Vandebriel RJ. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol 2008, 9:21. 10.1186/1471-2172-9-21, 2409298, 18498620.
31. Hem SL, HogenEsch H, Middaugh CR, Volkin DB. Preformulation studies--The next advance in aluminum adjuvant-containing vaccines. Vaccine 2010, 28:4868-4870. 10.1016/j.vaccine.2010.05.007, 20488265.
32. Clapp T, Siebert P, Chen D, Jones BL. Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability. J Pharm Sci 2011, 100:388-401. 10.1002/jps.22284, 20740674.